Targeting CD39 Toward Activated Platelets Reduces Systemic Inflammation and Improves Survival in Sepsis: A Preclinical Pilot Study
Tiago Granja, Andreas Koerner, Christian Gluck, Jan David Hohmann, Xiaowei Wang, David Koehler, Ariane Streissenberger, Harshal H Nandurkar, Valbona Mirakaj, Peter Rosenberger, Karlheinz Peter, Andreas Straub
CRITICAL CARE MEDICINE | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
OBJECTIVES: Sepsis is associated with a systemic inflammatory reaction, which can result in a life-endangering organ dysfunction. Pro-inflammatory responses during sepsis are characterized by increased activation of leukocytes and platelets, formation of platelet-neutrophil aggregates, and cytokine production. Sequestration of platelet-neutrophil aggregates in the microvasculature contributes to tissue damage during sepsis. At present no effective therapeutic strategy to ameliorate these events is available. In this preclinical pilot study, a novel anti-inflammatory approach was evaluated, which targets nucleoside triphosphate hydrolase activity toward activated platelets via a recombinant f..View full abstract
Awarded by German Research Foundation (Deutsche Forschungsgemeinschaft [DFG], Bonn, Germany)
Awarded by Interdisciplinary Center for Clinical Research (IZKF) program of the University of Tubingen, Germany
Supported, in part, by grants from the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG], Bonn, Germany) to Dr. Straub (grant number STR-687/4-1); Prof. Rosenberger (grant number DFG-RO 3672/6-2); and Prof. Mirakaj (MI-1506/4-1) and the Interdisciplinary Center for Clinical Research (IZKF) program of the University of Tubingen, Germany (grant number IZKF-No. PK 2015-1-05; granted to Prof. Rosenberger and Mr. Gluck); by a grant of the Dr. Karl Kuhn Foundation to Dr. Straub; and Dr. Xang was supported by a future leader fellowship of the National Heart Foundation of Australia.